Kinase-dependent Regulation of Monoamine Neurotransmitter Transporters

被引:72
作者
Bermingham, Daniel P. [1 ]
Blakely, Randy D. [1 ,2 ,3 ,4 ]
机构
[1] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Med Ctr, Dept Psychiat, Nashville, TN USA
[3] Florida Atlantic Univ, Dept Biomed Sci, Charles E Schmidt Coll Med, Jupiter, FL USA
[4] Florida Atlantic Univ, Inst Brain, Room 109 MC-17,5353 Parkside Dr, Jupiter, FL 33458 USA
基金
美国国家卫生研究院;
关键词
HUMAN DOPAMINE TRANSPORTER; HUMAN SEROTONIN TRANSPORTER; ACTIVATED PROTEIN-KINASE; HUMAN NOREPINEPHRINE TRANSPORTER; TRAFFICKING-INDEPENDENT REGULATION; SINGLE-NUCLEOTIDE POLYMORPHISMS; AMINOBUTYRIC-ACID TRANSPORTERS; BIOGENIC-AMINE TRANSPORTERS; NEUROTROPHIC FACTOR BDNF; CELL-SURFACE EXPRESSION;
D O I
10.1124/pr.115.012260
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Modulation of neurotransmission by the monoamines dopamine (DA), norepinephrine (NE), and serotonin (5-HT) is critical for normal nervous system function. Precise temporal and spatial control of this signaling in mediated in large part by the actions of monoamine transporters (DAT, NET, and SERT, respectively). These transporters act to recapture their respective neurotransmitters after release, and disruption of clearance and reuptake has significant effects on physiology and behavior and has been linked to a number of neuropsychiatric disorders. To ensure adequate and dynamic control of these transporters, multiple modes of control have evolved to regulate their activity and trafficking. Central to many of these modes of control are the actions of protein kinases, whose actions can be direct or indirectly mediated by kinase-modulated protein interactions. Here, we summarize the current state of our understanding of how protein kinases regulate monoamine transporters through changes in activity, trafficking, phosphorylation state, and interacting partners. We highlight genetic, biochemical, and pharmacological evidence for kinase-linked control of DAT, NET, and SERT and, where applicable, provide evidence for endogenous activators of these pathways. We hope our discussion can lead to a more nuanced and integrated understanding of how neurotransmitter transporters are controlled and may contribute to disorders that feature perturbed monoamine signaling, with an ultimate goal of developing better therapeutic strategies.
引用
收藏
页码:888 / 953
页数:66
相关论文
共 401 条
[1]   Flux coupling in the human serotonin transporter [J].
Adams, SV ;
DeFelice, LJ .
BIOPHYSICAL JOURNAL, 2002, 83 (06) :3268-3282
[2]   PROTEIN-KINASE-C REGULATES MARCKS CYCLING BETWEEN THE PLASMA-MEMBRANE AND LYSOSOMES IN FIBROBLASTS [J].
ALLEN, LAH ;
ADEREM, A .
EMBO JOURNAL, 1995, 14 (06) :1109-1121
[3]   Nongenomic mechanisms of physiological estrogen-mediated dopamine efflux [J].
Alyea, Rebecca A. ;
Watson, Cheryl S. .
BMC NEUROSCIENCE, 2009, 10
[4]  
Amara S.G., 1998, NEUROTRANSMITTER TRA
[5]   p38 MAP kinase activation does not stimulate serotonin transport in rat brain: Implications for sickness behaviour mechanisms [J].
Andreetta, Filippo ;
Barnes, Nicholas M. ;
Wren, Paul B. ;
Carboni, Lucia .
LIFE SCIENCES, 2013, 93 (01) :30-37
[6]   Tyrosine Phosphorylation of the Human Serotonin Transporter: A Role in the Transporter Stability and Function [J].
Annamalai, Balasubramaniam ;
Mannangatti, Padmanabhan ;
Arapulisamy, Obulakshmi ;
Shippenberg, Toni S. ;
Jayanthi, Lankupalle D. ;
Ramamoorthy, Sammanda .
MOLECULAR PHARMACOLOGY, 2012, 81 (01) :73-85
[7]   Involvement of threonine 258 and serine 259 motif in amphetamine-induced norepinephrine transporter endocytosis [J].
Annamalai, Balasubramaniam ;
Mannangatti, Padmanabhan ;
Arapulisamy, Obulakshmi ;
Ramamoorthy, Sammanda ;
Jayanthi, Lankupalle D. .
JOURNAL OF NEUROCHEMISTRY, 2010, 115 (01) :23-35
[8]   Calcium-dependent inhibition of synaptosomal serotonin transport by the α2-adrenoceptor agonist 5-bromo-N-[4,5-dihydro-1H-imidazol-2-yl]-6-quinoxalinamine (UK14304) [J].
Ansah, TA ;
Ramamoorthy, S ;
Montañez, S ;
Daws, LC ;
Blakely, RD .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 305 (03) :956-965
[9]  
Apparsundaram S, 2001, J PHARMACOL EXP THER, V299, P666
[10]  
Apparsundaram S, 1998, J PHARMACOL EXP THER, V287, P733